Stifel Financial Corp Sells 8,881 Shares of Edwards Lifesciences Co. (NYSE:EW)

Stifel Financial Corp reduced its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 3.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 223,857 shares of the medical research company's stock after selling 8,881 shares during the period. Stifel Financial Corp's holdings in Edwards Lifesciences were worth $16,572,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of EW. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences in the fourth quarter valued at $26,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Edwards Lifesciences in the fourth quarter valued at $30,000. Roble Belko & Company Inc acquired a new position in Edwards Lifesciences in the fourth quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 0.5 %

EW stock traded down $0.36 during midday trading on Thursday, reaching $75.13. The company had a trading volume of 884,377 shares, compared to its average volume of 4,985,533. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $44.17 billion, a P/E ratio of 10.80, a PEG ratio of 4.82 and a beta of 1.15. The company has a 50 day moving average of $71.03 and a two-hundred day moving average of $71.23.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the prior year, the firm earned $0.66 EPS. The company's revenue was up 6.2% compared to the same quarter last year. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,555,402. This trade represents a 12.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company's stock, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock worth $5,163,062 in the last 90 days. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have commented on EW. Royal Bank of Canada restated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Robert W. Baird boosted their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Truist Financial cut their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Finally, Canaccord Genuity Group raised their price target on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $79.45.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.